4.4 Article

Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein

Related references

Note: Only part of the references are listed.
Article Cell Biology

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

Mimi M. M. Hou et al.

Summary: Two clinical trials were conducted to evaluate two vaccines against Plasmodium vivax. The PvDBPII/Matrix-M vaccine, given in a delayed dosing regimen, showed the highest antibody responses and reduced parasite multiplication rate by 51% compared to controls. These results support further evaluation of the PvDBPII/Matrix-M P. vivax vaccine.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Immunology

Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants

Marianna Agudelo et al.

Summary: This paper describes the plasma and memory antibody response in a cohort of SARS-CoV-2 Gamma-infected individuals in Brazil. The results show that potent antibody neutralization is limited to Gamma and Beta variants, with lower neutralizing activity against other variants. Additionally, antibodies elicited by Gamma infection tend to recognize Class 3 epitopes more.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

Article Medicine, General & Internal

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Kassoum Kayentao et al.

Summary: A phase 2 trial conducted in Mali showed that a single intravenous infusion of CIS43LS was safe and effective in preventing Plasmodium falciparum infection over a 6-month malaria season.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Medicine, General & Internal

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Kassoum Kayentao et al.

Summary: A phase 2 trial in Mali showed that CIS43LS was protective against P. falciparum infection over a 6-month malaria season, with 40 mg dosage showing 88.2% efficacy and 10 mg dosage showing 75.0% efficacy compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Microbiology

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein

Lawrence Wang et al.

Summary: While combinations of mAbs against the repeat and C-terminal regions of PfCSP do not provide additional protection in vivo, repeat mAbs do offer increased protection when combined with vaccine-induced polyclonal antibodies against PfCSP.

PLOS PATHOGENS (2021)

Article Medicine, General & Internal

A Monoclonal Antibody for Malaria Prevention

M. R. Gaudinski et al.

Summary: This study evaluated the safety, pharmacokinetics, and efficacy of a new long-acting monoclonal antibody CIS43LS against malaria. Results showed that administration of CIS43LS effectively prevented malaria after controlled infection, and there was a dose-dependent relationship between serum concentrations of CIS43LS and protective efficacy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Microbiology

Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques

Koen K. A. Van Rompay et al.

Summary: The combination of the potent monoclonal antibodies C135-LS and C144-LS improved clinical symptoms, reduced virus replication in the respiratory tract, and significantly decreased lung inflammation in macaques infected with SARS-CoV-2. These findings suggest potential therapeutic benefits of these antibodies in early COVID-19 infection.

PLOS PATHOGENS (2021)

Article Cell Biology

Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies

Alexandra C. Willcox et al.

Summary: The study found that pre-existing antibodies will interact favorably with vaccine-induced RH5 antibodies, supporting RH5 vaccine trials in malaria-endemic regions.

CELL REPORTS MEDICINE (2021)

Article Biochemistry & Molecular Biology

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Aleksandr Ianevski et al.

NUCLEIC ACIDS RESEARCH (2020)

Article Biochemistry & Molecular Biology

Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion

Manuel Alfonso Patarroyo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Biology

CRISPR-Cas9 Genome Editing of Plasmodium knowlesi

Franziska Mohring et al.

BIO-PROTOCOL (2020)

Article Infectious Diseases

Growing evidence of Plasmodium vivax across malaria-endemic Africa

Katherine A. Twohig et al.

PLOS NEGLECTED TROPICAL DISEASES (2019)

Article Medicine, General & Internal

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

Sabue Mulangu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Biochemistry & Molecular Biology

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

Neville K. Kisalu et al.

NATURE MEDICINE (2018)

Article Multidisciplinary Sciences

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Pilar Mendoza et al.

NATURE (2018)

Article Infectious Diseases

Genetic diversity in two Plasmodium vivax protein ligands for reticulocyte invasion

Camille Roesch et al.

PLOS NEGLECTED TROPICAL DISEASES (2018)

Article Medicine, Research & Experimental

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies

Ruth O. Payne et al.

JCI INSIGHT (2017)

Article Multidisciplinary Sciences

Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein

Edwin Chen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Review Infectious Diseases

A systematic review of sub-microscopic Plasmodium vivax infection

Clarissa M. Moreira et al.

MALARIA JOURNAL (2015)

Article Infectious Diseases

Plasmodium vivax Transmission in Africa

Rosalind E. Howes et al.

PLOS NEGLECTED TROPICAL DISEASES (2015)

Article Parasitology

The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon

Tais Nobrega de Sousa et al.

MEMORIAS DO INSTITUTO OSWALDO CRUZ (2014)

Article Multidisciplinary Sciences

Adaptation of the genetically tractable malaria pathogen Plasmodium knowlesi to continuous culture in human erythrocytes

Robert W. Moon et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Article Biochemistry & Molecular Biology

Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC

Joseph D. Batchelor et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)

Article Biochemistry & Molecular Biology

A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines

Dorota Smolarek et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2010)

Article Multidisciplinary Sciences

Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people

Didier Menard et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Article Biochemical Research Methods

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

Thomas Tiller et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2008)

Article Infectious Diseases

Polymorphism patterns in Duffy-binding protein among Thai Plasmodium vivax isolates

Panita Gosi et al.

MALARIA JOURNAL (2008)

Article Multidisciplinary Sciences

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection

Christopher L. King et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Article Biochemistry & Molecular Biology

Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion

D Hans et al.

MOLECULAR MICROBIOLOGY (2005)